SciClone

SciClone logo

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases.

SciClone’s lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of hepatocellular carcinoma, malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation with over 120 members.

A key part of SciClone’s strategy is to leverage its advantage in China by in-licensing and detailing other products, such as the DC Bead, to broaden its portfolio in this rapidly gorwing pharmaceutical market.

SciClone Pharmaceuticals International Ltd. (SPIL), is the interntional sales arm of SciClone Pharmaceutical, Inc. SPIL generated nearly $27.8 million in ZADAXIN® sales in 2005. SPIL is headquartered in Hong Kong, with regional offices in Beijing, Shanghai, Siingapore and Grand Cayman, B.W.I.

SPIL has obtained regulatory approvals for ZADAXIN in various countries for the treatment of hepatitis B, hepatitis C, cancer, and for the use as a vaccine adjuvant. ZADAXIN is now approved for sale in over 30 countries worldwide including China, the Pacific Rim, the Middle East, Latin America, Eastern Europe and Italy.

Hong Kong Headquarters

Hans Schmid
Managing Director, SPIL
SciClone Pharmaceuticals Intl Ltd..
Room 3401A, Windsor House
311 Gloucester Road
Causeway Bay
Hong Kong
hschmid@spil.org

Hilda Ng
Office Manager
SciClone Pharmaceuticals Intl Ltd.
Room 3401A, Windsor House
311 Gloucester Road
Causeway Bay
Hong Kong
Phone 852-2510-0118
Fax 852-2508-1500
hng@spil.org

Shanghai

SciClone Pharmaceuticals Intl Ltd.
Room 2101-03
Shanghai Times Square
93 Huai Hai Zhong Road
Shanghai 200021
China
Phone 86-21-63910909
Fax 86-21-63918090
shanghai@spil.org

Beijing

SciClone Pharmaceuticals Intl Ltd.
Room 3102, Office Tower A
Fortune Plaza
No. 7 Dong Sanhuan Zhong Lu
Chao Yang District
Beijing 100020
China
Phone 8610-6530-9016
Fax 8610-6530-9020
beijing@spil.org

www.scicloneinternational.com

Regulatory notices and product safety data

Worldwide (excluding USA)

Bead Block™ is CE marked and indicated for the treatment of a variety of hypervascular tumours (including Uterine Fibroids) and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block instructions for use.

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). Both indications may not be available in your territory. For full prescribing information please refer to DC Bead instructions for use.

DC BeadM1™ is indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead M1 instructions for use.

USA

In the USA, Bead Block™ is indicated for the treatment of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block USA Instructions for use.

LC Bead™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead instructions for use.

LC Bead M1™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead M1 instructions for use.

DC Bead is not currently available for sale or distribution in the USA. Both indications may not be available in your territory. 

DC Bead M1 is not currently available for sale or distributions in the USA. 

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

DC BeadM1 is primarily intended as an embolic agent to treat vessels supplying malignant colorectal cancer metastasised to the liver (mCRC). DC BeadM1 is also compatible with irinotecan, which can be loaded prior to embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the mCRC after embolisation. For full prescribing information please refer to DC BeadM1 Canada Instructions for Use  

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.

Hong Kong

PRECISION Bead™ is indicated for the delivery of Doxorubicin, a chemotherapeutic agent for the treatment of malignant hypervascular tumours, where Trans Arterial Embolisation (TAE) is not contraindicated.